Your browser doesn't support javascript.
loading
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
Nan, Yuemin; An, Jihong; Bao, Jianfeng; Chen, Hongsong; Chen, Yu; Ding, Huiguo; Dou, Xiaoguang; Duan, Zhongping; Fan, Jiangao; Gao, Yanhang; Han, Tao; Han, Ying; Hu, Peng; Huang, Yan; Huang, Yuan; Jia, Jidong; Jiang, Jiaji; Jiang, Ying'an; Li, Jie; Li, Jun; Li, Rongkuan; Li, Shuchen; Li, Wengang; Li, Yufang; Lin, Shumei; Liu, Jingfeng; Liu, Shourong; Lu, Lungen; Lu, Qinghua; Luo, Xinhua; Ma, Xiong; Rao, Huiying; Ren, Hong; Ren, Wanhua; Shang, Jia; Shi, Li; Su, Minghua; Wang, Bingyuan; Wang, Rongqi; Wei, Lai; Wen, Zhili; Wu, Biao; Wu, Jing; Xin, Shaojie; Xing, Huichun; Xu, Jinghang; Yan, Ming; Yang, Jiming; Yang, Jinhui; Yang, Li.
Affiliation
  • Nan Y; Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang 050051, China. Electronic address: nanyuemin@hebmu.edu.cn.
  • An J; Department of Infectious Diseases, Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia 010017, China.
  • Bao J; Department of Hepatology, Hangzhou Xixi Hospital, Hangzhou 310023, China.
  • Chen H; Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, Peking University People's Hospital, Beijing 100044, China.
  • Chen Y; Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
  • Ding H; Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
  • Dou X; Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang 110022, China.
  • Duan Z; Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
  • Fan J; Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
  • Gao Y; Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China.
  • Han T; Department of Hepatology and Gastroenterology, Tianjin Third Central Hospital, Tianjin 300170, China.
  • Han Y; Department of Gastroenterology, The First Affiliated Hospital of Air Force Medical University, Xi'an 710032, China.
  • Hu P; Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
  • Huang Y; Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha 410008, China.
  • Huang Y; Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital, Beijing 102218, China.
  • Jia J; Liver Research Centre, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
  • Jiang J; Liver Diseases Research Centre, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350001, China.
  • Jiang Y; Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, China.
  • Li J; Department of Microbiology, Peking University Health Science Centre, Beijing 100191, China.
  • Li J; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
  • Li R; Department of Infectious Diseases, The Second Hospital of Dalian Medical University, Dalian 116027, China.
  • Li S; Department of Infectious Diseases, The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China.
  • Li W; Radiation Oncology Centre, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing 100039, China.
  • Li Y; Department of Infectious Diseases, The General Hospital of Ningxia Medical University, Yinchuan 750004, China.
  • Lin S; Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
  • Liu J; Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China.
  • Liu S; Department of Infectious Diseases, Hangzhou Xixi Hospital, Hangzhou 310023, China.
  • Lu L; Department of Gastroenterology Shanghai General Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
  • Lu Q; Department of Liver Diseases, The Fourth People's Hospital of Qinghai Province, Xining 810001, China.
  • Luo X; Department of Infectious Diseases, Guizhou Provincial People's Hospital, Guiyang 550002, China.
  • Ma X; Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Digestive Diseases, Shanghai 200001, China.
  • Rao H; Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, Peking University People's Hospital, Beijing 100044, China.
  • Ren H; The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
  • Ren W; Department of Infectious Diseases, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China.
  • Shang J; Department of Infectious Diseases, Henan Province People's Hospital, Zhengzhou University People's Hospital and Henan University People's Hospital, Zhengzhou 450003, China.
  • Shi L; Department of Infectious Diseases, People's Hospital of Tibet Autonomous Region, Lhasa 850000, China.
  • Su M; Department of Infectious Diseases, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
  • Wang B; Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang 110001, China.
  • Wang R; Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
  • Wei L; Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital, Beijing 102218, China.
  • Wen Z; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang 330008, China.
  • Wu B; Department of Infectious Diseases, Hainan General Hospital, Haikou 570311, China.
  • Wu J; Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
  • Xin S; Liver Failure Treatment and Research Centre, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing 100039, China.
  • Xing H; Centre for Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
  • Xu J; Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.
  • Yan M; Department of Hepatology and Gastroenterology, Qilu Hospital, Shandong University, Jinan 250012, China.
  • Yang J; Tianjin Second People's Hospital, Tianjin 300192, China.
  • Yang J; Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650000, China.
  • Yang L; West China Hospital, Sichuan University, Chengdu 610041, China.
J Hepatol ; 75(2): 454-461, 2021 08.
Article in En | MEDLINE | ID: mdl-34019941
Fatty liver disease associated with metabolic dysfunction is of increasing concern in mainland China, the world's most populous country. The incidence of fatty liver disease is highest in China, surpassing the incidence in European countries and the USA. An international consensus panel recently published an influential report recommending a novel definition of fatty liver disease associated with metabolic dysfunction. This recommendation includes a switch in name from non-alcoholic fatty liver disease (NAFLD) to metabolic (dysfunction)-associated fatty liver disease (MAFLD) and adoption of a set of positive criteria for disease diagnosis that are independent of alcohol intake or other liver diseases. Given the unique importance of this proposal, the Chinese Society of Hepatology (CSH) invited leading hepatologists and gastroenterologists representing their respective provinces and cities to reach consensus on alternative definitions for fatty liver disease from a national perspective. The CSH endorses the proposed change from NAFLD to MAFLD (supported by 95.45% of participants). We expect that the new definition will result in substantial improvements in health care for patients and advance disease awareness, public health policy, and political, scientific and funding outcomes for MAFLD in China.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Fatty Liver / Gastroenterology Type of study: Guideline Limits: Humans Country/Region as subject: Asia Language: En Year: 2021 Type: Article

Full text: 1 Database: MEDLINE Main subject: Fatty Liver / Gastroenterology Type of study: Guideline Limits: Humans Country/Region as subject: Asia Language: En Year: 2021 Type: Article